RIP1 kinase inhibitor 1
Based on 1 Customer Validation
RIP1 kinase inhibitor 1 (compound 22) is a highly potent, orally available, and brain-penetrating RIP1 kinase inhibitor (pKi=9.04).
For research use only. We do not sell to patients.
- Purity: 99.96%
- CAS No.: 2095515-38-9
- Formula: C24H20ClN5O3
- Molecular Weight:461.90
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
NF-κB Signaling Compound Library
HY-L014
-
Heterocyclic Compound Library
HY-L138
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
MCE Bioactive Compound Library
HY-L001V
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Biological Activity
pKi: 9.04 (RIP1 kinase)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | IC50 |
2 nM
Compound: 22
|
Induction of necroptosis in human HT-29 cells assessed as increase in TNFalpha/AT-406/zVAD-FMK-induced LDH release preincubated with cells followed by TNFalpha/AT-406/zVAD-FMK addition measured after 16 to 20 hrs by CytoTox 96 nonradioactive cytotoxicity
Induction of necroptosis in human HT-29 cells assessed as increase in TNFalpha/AT-406/zVAD-FMK-induced LDH release preincubated with cells followed by TNFalpha/AT-406/zVAD-FMK addition measured after 16 to 20 hrs by CytoTox 96 nonradioactive cytotoxicity
|
[PMID: 29485864] |
| L929 | IC50 |
15 nM
Compound: 22
|
Induction of necroptosis in mouse L929 cells assessed as increase in TNFalpha/zVAD-FMK-induced LDH release preincubated for 30 mins followed by TNFalpha/zVAD-FMK addition measured after 4 hrs by CytoTox 96 nonradioactive cytotoxicity assay
Induction of necroptosis in mouse L929 cells assessed as increase in TNFalpha/zVAD-FMK-induced LDH release preincubated for 30 mins followed by TNFalpha/zVAD-FMK addition measured after 4 hrs by CytoTox 96 nonradioactive cytotoxicity assay
|
[PMID: 29485864] |
RIP1 kinase inhibitor 1 (compound 22) strongly suppresses necroptotic cell death and phosphorylation of MLKL(pMLKL) in human colorectal adenocarcinoma HT-29 cells (nectoptosis, IC50=2 nM; pMLKL, IC50=1.3 nM) as well as mouse L-cells NCTC 929 (nectoptosis, IC50=15 nM; pMLKL, IC50=2.7 nM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2095515-38-9
-
Appearance Solid
-
Molecular Weight 461.90
-
Formula C24H20ClN5O3
-
Color White to yellow
-
SMILES
N#CC1=CC=C2N(C)C([C@@H](N3CCC4=C(Cl)N(CC5=CC=CC=C5)N=C4C3=O)COC2=C1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 200 mg/mL (432.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 5 mg/mL (10.82 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yoshikawa M, et al. Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine Derivatives as Potent, OrallyAvailable, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships. J Med Chem. 2018 Mar 22;61(6):2384-2409. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1650 mL | 10.8249 mL | 21.6497 mL | 54.1243 mL |
| 5 mM | 0.4330 mL | 2.1650 mL | 4.3299 mL | 10.8249 mL | |
| 10 mM | 0.2165 mL | 1.0825 mL | 2.1650 mL | 5.4124 mL | |
| 15 mM | 0.1443 mL | 0.7217 mL | 1.4433 mL | 3.6083 mL | |
| 20 mM | 0.1082 mL | 0.5412 mL | 1.0825 mL | 2.7062 mL | |
| 25 mM | 0.0866 mL | 0.4330 mL | 0.8660 mL | 2.1650 mL | |
| 30 mM | 0.0722 mL | 0.3608 mL | 0.7217 mL | 1.8041 mL | |
| 40 mM | 0.0541 mL | 0.2706 mL | 0.5412 mL | 1.3531 mL | |
| 50 mM | 0.0433 mL | 0.2165 mL | 0.4330 mL | 1.0825 mL | |
| 60 mM | 0.0361 mL | 0.1804 mL | 0.3608 mL | 0.9021 mL | |
| 80 mM | 0.0271 mL | 0.1353 mL | 0.2706 mL | 0.6766 mL | |
| 100 mM | 0.0216 mL | 0.1082 mL | 0.2165 mL | 0.5412 mL |
RIP1 kinase inhibitor 1 Related Classifications
HY-111409 Related Classifications
Powered by Bioz